Biotech News

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

GoodRx (GDRX)GoodRx2026-05-01 12:10 ESTFinancing

Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month Brief Summary: GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month Available at GoodRx’s nationwide pharmacy network Adds an oral option to the Ozempic treatment

Open original release

Related news

GDRXGoodRx2026-05-27 13:00 EST

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GDRXGoodRx2026-05-06 20:05 EST

GoodRx Reports First Quarter 2026 Results

GDRXGoodRx2026-04-17 20:05 EST

GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

GDRXGoodRx2026-04-15 13:00 EST

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GDRXGoodRx2026-04-09 11:30 EST

GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GDRXGoodRx2026-03-11 13:00 EST

GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

GDRXGoodRx2026-03-06 14:00 EST

GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

GDRXGoodRx2026-02-25 21:05 EST

GoodRx Reports Fourth Quarter and Full Year 2025 Results

GDRXGoodRx2026-02-24 14:00 EST

GoodRx Expands Into Employer Market With Launch of “GoodRx Employer Direct”

GDRXGoodRx2026-02-06 00:44 EST

GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

View all latest news

GoodRx

GoodRx is a consumer healthcare platform focused on drug pricing, pharmacy access, and savings tools for patients.

Recent company news

GDRXBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

GDRXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

GDRXMolina Healthcare2026-07-22 20:15 EST

Molina Healthcare Reports Second Quarter 2026 Financial Results

GDRXAxon Enterprise, Inc.2026-07-22 20:01 EST

Axon to Release Second Quarter 2026 Earnings on August 5, 2026

GDRXGSK plc2026-07-22 11:21 EST

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Stock data

Close: 2.87 USD
Market cap: 999.09M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States